Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Sales | 100,041 | 100,533 | 96,163 | 50,897 | 26,930 |
| Gross Profit | 100,041 | 100,533 | 96,163 | 50,897 | 26,930 |
| Operating Expenses | 144,111 | 148,644 | 123,998 | 144,074 | 66,431 |
| Operating Income | -44,070 | -48,111 | -27,835 | -93,177 | -39,501 |
| Interest Expense | 0 | 0 | 872 | 1,083 | 1,029 |
| Other Income | 1,069 | 1,103 | 3,177 | 14,039 | 5,922 |
| Pre-tax Income | -43,001 | -47,008 | -25,530 | -80,221 | -34,608 |
| Income Tax | 514 | 582 | 719 | 5,245 | N/A |
| Net Income Continuous | -43,515 | -47,590 | -26,249 | -85,466 | -34,608 |
| Net Income | $-43,515 | $-47,590 | $-26,249 | $-85,466 | $-34,608 |
| EPS Basic Total Ops | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 |
| EPS Basic Continuous Ops | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 |
| EPS Diluted Total Ops | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 |
| EPS Diluted Continuous Ops | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 |
| EBITDA(a) | $-39,129 | $-42,119 | $-22,109 | $-89,095 | $-35,431 |